181 related articles for article (PubMed ID: 20527720)
1. Epidemiological survey of haemophiliacs with inhibitors in France: orthopaedic status, quality of life and cost--the 'Statut Orthopédique des Patients Hémophiles' avec Inhibiteur study.
Stieltjes N; Torchet MF; Misrahi L; Roussel-Robert V; Lambert T; Guérois C; Bertrand MA; Briquel ME; Borel-Derlon A; Dirat G
Blood Coagul Fibrinolysis; 2009 Jan; 20(1):4-11. PubMed ID: 20527720
[TBL] [Abstract][Full Text] [Related]
2. The orthopaedic status of severe haemophiliacs in Spain.
Aznar JA; Magallón M; Querol F; Gorina E; Tusell JM
Haemophilia; 2000 May; 6(3):170-6. PubMed ID: 10792475
[TBL] [Abstract][Full Text] [Related]
3. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group.
Gringeri A; Mantovani LG; Scalone L; Mannucci PM;
Blood; 2003 Oct; 102(7):2358-63. PubMed ID: 12816859
[TBL] [Abstract][Full Text] [Related]
4. Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres.
Nerich V; Tissot E; Faradji A; Demesmay K; Bertrand MA; Lorenzini JL; Briquel ME; Pouzol P; Woronoff-Lemsi MC
Pharm World Sci; 2008 Jun; 30(3):287-92. PubMed ID: 18085428
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of haemophilia treatment: a cross-national assessment.
Lippert B; Berger K; Berntorp E; Giangrande P; van den Berg M; Schramm W; Siebert U;
Blood Coagul Fibrinolysis; 2005 Oct; 16(7):477-85. PubMed ID: 16175006
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor economics.
Teitel J
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S14-7. PubMed ID: 16690371
[TBL] [Abstract][Full Text] [Related]
7. [The orthopaedic status of a selected severe haemophilia group].
Windyga J; Stefańska E; Lopaciuk S; Juszyński A; Woźniak D; Strzelecki O
Pol Arch Med Wewn; 2005 Jun; 113(6):562-9. PubMed ID: 16454446
[TBL] [Abstract][Full Text] [Related]
8. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.
Ullman M; Hoots WK
Haemophilia; 2006 Dec; 12 Suppl 6():74-9; discussion 79-80. PubMed ID: 17123398
[TBL] [Abstract][Full Text] [Related]
9. Is haemophilia prophylaxis achievable in the context of self-sufficiency?
Nilsson IM
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S71-5. PubMed ID: 7795143
[TBL] [Abstract][Full Text] [Related]
10. Recombinant clotting factors in the treatment of hemophilia.
Lee C
Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
[No Abstract] [Full Text] [Related]
11. Cost of care of haemophilia with inhibitors.
Di Minno MN; Di Minno G; Di Capua M; Cerbone AM; Coppola A
Haemophilia; 2010 Jan; 16(1):e190-201. PubMed ID: 19845772
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat.haemophiles@cch.ap-hop-paris.fr.
Molho P; Rolland N; Lebrun T; Dirat G; Courpied JP; Croughs T; Duprat I; Sultan Y
Haemophilia; 2000 Jan; 6(1):23-32. PubMed ID: 10632738
[TBL] [Abstract][Full Text] [Related]
13. Outcome measures for adult and pediatric hemophilia patients with inhibitors.
Hermans C; Auerswald G; Benson G; Dolan G; Duffy A; Jiménez-Yuste V; Ljung R; Morfini M; Lambert T; Osooli M; Zupančić Šalek S
Eur J Haematol; 2017 Aug; 99(2):103-111. PubMed ID: 28332238
[TBL] [Abstract][Full Text] [Related]
14. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs.
Tagliaferri A; Franchini M; Coppola A; Rivolta GF; Santoro C; Rossetti G; Feola G; Zanon E; Dragani A; Iannaccaro P; Radossi P; Mannucci PM
Haemophilia; 2008 Sep; 14(5):945-51. PubMed ID: 18540895
[TBL] [Abstract][Full Text] [Related]
15. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice.
Franchini M; Mannucci PM
Br J Clin Pharmacol; 2011 Oct; 72(4):553-62. PubMed ID: 21204915
[TBL] [Abstract][Full Text] [Related]
17. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
Roosendaal G; Lafeber FP
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX.
Nilsson IM; Hedner U
Scand J Haematol; 1976 May; 16(5):369-82. PubMed ID: 951577
[TBL] [Abstract][Full Text] [Related]
19. Healthcare resource utilization among haemophilia A patients in the United States.
Valentino LA; Pipe SW; Tarantino MD; Ye X; Xiong Y; Luo MP
Haemophilia; 2012 May; 18(3):332-8. PubMed ID: 22044662
[TBL] [Abstract][Full Text] [Related]
20. [Quality of life of young patients with haemophilia in Europe].
Bullinger M; Gringeri A; von Mackensen S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jun; 51(6):637-45. PubMed ID: 18481032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
